Revvity, Inc. (RVTY) Return on Equity (ROE): 3.35%
Is Revvity, Inc.’s return on equity (ROE) high or low?
Revvity, Inc.'s return on equity (ROE) of 3.35% is 56% below its 5-year average of 7.68%, near the low end of its 5-year range (-1.50%–19.49%).
As of Wednesday, June 17, 2026. 6.82% below its 12-month average of 3.59%.
RVTY Return on Equity (ROE) Chart
RVTY Average Return on Equity (ROE) Chart
RVTY Current vs Average Return on Equity (ROE) Chart
RVTY Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
3.35%
RETURN ON EQUITY (ROE) AVG TTM
3.59%
RETURN ON EQUITY (ROE) AVG 3Y
3.35%
RETURN ON EQUITY (ROE) AVG 5Y
7.68%
RETURN ON EQUITY (ROE) AVG 10Y
8.08%
RETURN ON EQUITY (ROE) AVG 15Y
8.03%
RETURN ON EQUITY (ROE) AVG 20Y
6.49%
CURRENT VS TTM AVG
-6.82%
CURRENT VS 3Y AVG
+0.00%
CURRENT VS 5Y AVG
-56.40%
CURRENT VS 10Y AVG
-58.53%
CURRENT VS 15Y AVG
-58.30%
CURRENT VS 20Y AVG
-48.41%
RVTY Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 3.35% | 3.59% | 3.35% | 7.68% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Baxter International Inc. (BAX)vs › | $10.19B | -18.17% | -12.46% | -8.76% | -1.37% |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 10.36% | 10.54% | 10.84% | 19.93% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 2.86% | 4.70% | 4.67% | 11.22% |
| Solventum Corporation (SOLV)vs › | $12.91B | 28.82% | 23.51% | 17.50% | 13.68% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | -6.28% | -2.13% | 6.32% | 9.65% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 76.95% | 73.63% | 65.34% | 49.74% |
| Tempus AI, Inc. (TEM)vs › | $8.51B | -72.74% | -651.33% | -315.37% | -198.08% |
| DaVita Inc. (DVA)vs › | $13.46B | -114.70% | 329.18% | 200.63% | 164.66% |
Return Analysis
ROE
3.4%
ROA
2.0%
Revvity, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Revvity, Inc. (RVTY)?
- The return on equity (ROE) for RVTY stock is 3.35%.
- Is Revvity, Inc.'s return on equity (ROE) high or low?
- Revvity, Inc.'s return on equity (ROE) of 3.35% is 56% below its 5-year average of 7.68%, near the low end of its 5-year range (-1.50%–19.49%).
- What is the TTM average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The TTM average return on equity (ROE) for RVTY stock is 3.59%.
- What is the 3Y average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The 3Y average return on equity (ROE) for RVTY stock is 3.35%.
- What is the 5Y average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The 5Y average return on equity (ROE) for RVTY stock is 7.68%.
- What is the 10Y average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The 10Y average return on equity (ROE) for RVTY stock is 8.08%.
- What is the 15Y average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The 15Y average return on equity (ROE) for RVTY stock is 8.03%.
- What is the 20Y average return on equity (ROE) for Revvity, Inc. (RVTY)?
- The 20Y average return on equity (ROE) for RVTY stock is 6.49%.
Revvity, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-28 | 3.33% |
| 2024-12-29 | 3.86% |
| 2023-12-31 | -1.50% |
| 2022-12-31 | 7.71% |
| 2021-12-31 | 13.21% |
| 2020-12-31 | 19.49% |
| 2019-12-31 | 8.09% |
| 2018-12-31 | 9.24% |
| 2017-12-31 | 4.51% |
| 2016-12-31 | 10.85% |
| 2015-12-31 | 10.07% |
| 2014-12-31 | 7.74% |
| 2013-12-31 | 8.42% |
| 2012-12-31 | 3.53% |
| 2011-12-31 | 0.06% |
| 2010-12-31 | 19.94% |
| 2009-12-31 | 5.25% |
| 2008-12-31 | 8.19% |
| 2007-12-31 | 8.44% |
| 2006-12-31 | 7.43% |
| 2005-12-31 | 4.95% |
| 2004-12-31 | 5.20% |
| 2003-12-31 | 3.93% |
| 2002-12-31 | -0.33% |
| 2001-12-31 | -0.05% |
| 2000-12-31 | 12.43% |
| 1999-12-31 | 5.16% |
| 1998-12-31 | 25.52% |
| 1997-12-31 | 10.27% |
| 1996-12-31 | 16.49% |
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh